Source comparison
MOTS-c Help Metabolic Syndrome Research: Comparison
MOTS-c Mitochondrial AMPK activation, increased oxidative phosphorylation +38–42% (HOMA-IR reduction in mice) Yes. Metabolic improvement exceeds weight loss Phase 2 ongoing (52-week endpoint trial) High. Isolates mitochondrial dysfunction from adiposity Metfor
This comparison does not assign a generated winner or score.
- MOTS-c
- Mitochondrial AMPK activation, increased oxidative phosphorylation
- +38–42% (HOMA-IR reduction in mice)
- Yes. Metabolic improvement exceeds weight loss
- Phase 2 ongoing (52-week endpoint trial)
- High. Isolates mitochondrial dysfunction from adiposity
- Metformin
- AMPK activation via complex I inhibition, reduced hepatic gluconeogenesis
- +25–30% (typical HOMA-IR reduction)
- Partial. Some effect independent of weight
- FDA-approved, decades of data
- Moderate. Pleiotropic effects complicate mechanism studies
- GLP-1 Agonists (semaglutide)
- Appetite suppression, delayed gastric emptying, incretin effect
- +40–50% at therapeutic dose
- No. Effect mediated primarily through weight loss
- FDA-approved for T2D and obesity
- Low for mitochondrial research. Works through different pathway
- Exercise Training
- Mitochondrial biogenesis, GLUT4 translocation, reduced inflammation
- +30–40% (dependent on adherence and intensity)
- Yes when volume-matched
- Gold standard comparator
- High but confounded by adherence variability
- Caloric Restriction
- Reduced oxidative stress, improved insulin signaling, weight loss
- +35–45% (with 7–10% weight loss)
- No. Entirely mediated by energy deficit
- Universally studied
- Low. Cannot isolate metabolic from adiposity effects
- The comparison underscores why MOTS-c help metabolic syndrome research matters for experimental design. GLP-1 agonists produce larger metabolic improvements but work through weight loss, making them unsuitable for studies isolating mitochondrial vs whole-body energy balance effects. Metformin activates AMPK but also inhibits Complex I, creating off-target effects that complicate interpretation. MOTS-c offers a cleaner tool for probing whether mitochondrial restoration alone. Without appetite suppression or caloric deficit. Can reverse insulin resistance.